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Abstract
Objective To assess the cost-effectiveness of a mobile health-supported lifestyle intervention compared with usual care.
Methods We conducted a cost-effectiveness analysis from the perspective of the publicly-funded health care system. We
estimated costs associated with the intervention and health care utilisation from ﬁrst antenatal care appointment through
delivery. We used bootstrap methods to quantify the uncertainty around cost‐effectiveness estimates. Health outcomes
assessed in this analysis were gestational weight gain (GWG; kg), incidence of excessive GWG, quality-adjusted life years
(QALYs), and incidence of large-for-gestational-age (LGA). Incremental cost-effectiveness ratios (ICERs) were calculated
as cost per QALY gained, cost per kg of GWG avoided, cost per case of excessive GWG averted, and cost per case of LGA
averted.
Results Total mean cost including intervention and health care utilisation was €3745 in the intervention group and €3471 in
the control group (mean difference €274, P = 0.08). The ICER was €2914 per QALY gained. Assuming a ceiling ratio of
€45,000, the probability that the intervention was cost‐effective based on QALYs was 79%. Cost per kg of GWG avoided
was €209. The cost-effectiveness acceptability curve (CEAC) for kg of GWG avoided reached a conﬁdence level of 95% at
€905, indicating that if one is willing to pay a maximum of an additional €905 per kg of GWG avoided, there is a 95%
probability that the intervention is cost-effective. Costs per case of excessive GWG averted and case of LGA averted were
€2117 and €5911, respectively. The CEAC for case of excessive GWG averted and for case of LGA averted reached a
conﬁdence level of 95% at €7090 and €25,737, respectively.
Conclusions Results suggest that a mobile-health lifestyle intervention could be cost-effective; however, a better understanding of the short- and long-term costs of LGA and excessive GWG is necessary to conﬁrm the results.

Introduction
These authors contributed equally as joint ﬁrst authors: Elizabeth J.
O’Sullivan, Slawa Rokicki
Supplementary information The online version of this article (https://
doi.org/10.1038/s41366-020-0531-9) contains supplementary
material, which is available to authorised users.
* Fionnuala M. McAuliffe
ﬁonnuala.mcauliffe@ucd.ie
1

UCD Perinatal Research Centre, School of Medicine, University
College Dublin, National Maternity Hospital Ireland,
Dublin, Ireland

2

School of Biological and Health Sciences, Technological
University Dublin, Dublin, Ireland

3

Geary Institute for Public Policy, University College Dublin,
Dublin, Ireland

4

Present address: Department of Health Behavior, Society, and
Policy, Rutgers School of Public Health, Piscataway, United States

Poor diet and exercise during pregnancy can result in
excessive gestational weight gain (GWG) and the onset of
glucose intolerance known as gestational diabetes mellitus
(GDM) [1]. Excessive GWG and GDM are associated with
costly short- and long-term outcomes for the pregnant
woman and her infant. Excessive GWG is associated with
increased risk of preterm delivery, as well as large-forgestational-age (LGA) and macrosomic infants [2, 3].
Excessive GWG has also been associated with both an
increased risk of early childhood obesity [4, 5] and an
increase in maternal body mass index (BMI) [6]. This is of
concern because obesity is consistently cited as a signiﬁcant
contributor to the global burden of disease and places a
signiﬁcant economic burden on health care systems [7].
Risks for mothers and infants, as well as increased costs
to the health care system, have provided the impetus for
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investigators to develop cost-effective interventions to
improve diet and exercise and reduce excessive weight
gained during pregnancy. This is particularly important
among women with an elevated BMI, for whom health
service usage and costs during pregnancy are increased by
23% and 37%, respectively [8], and whose children also
incur higher health care costs over their ﬁrst 18 years of life
[9]. A range of lifestyle interventions that promote dietary
and physical activity changes have been developed and
tested; systematic reviews of the effectiveness of these
interventions have concluded that they may be successful at
reducing weight gained during pregnancy and risk of preterm birth [10, 11]; however, little is known regarding how
cost-effective these interventions are from the perspective of
the health care system.
The objective of this study is to conduct a costeffectiveness analysis to evaluate the costs and consequences of providing a mobile health-supported lifestyle
intervention to women with an elevated BMI. To our
knowledge, this is the ﬁrst study to examine the costeffectiveness of using a mobile-phone app to improve
maternal and infant outcomes for pregnant women with an
elevated BMI.

Methods
The PEARs trial
The Pregnancy, Exercise And nutrition Research Study
(PEARs) was a single-centre randomised controlled trial
conducted within The National Maternity Hospital, Dublin,
Ireland; it is registered with Current Controlled Trials
(ISRCTN 29316280) and institutional ethical approval was
obtained. Participants provided written informed consent. A
detailed description of this trial has been published [12, 13].
Brieﬂy, women (n = 565) were recruited at their ﬁrst
antenatal appointment, between 10- and 15-weeks’ gestation. Women with a BMI of ≥25 kg/m2 and ≤39.9 kg/m2
were eligible to participate if they were between 18 and 45
years of age, with a singleton pregnancy, and owned a
smartphone. Women were excluded if they had experienced
GDM in a previous pregnancy, had any illness requiring
medical treatment or were unable to provide informed
written consent.

Description of the intervention
The aim of the PEARs trial was to assess whether a ‘healthy
lifestyle package,’ including dietary and exercise advice and
a smartphone app to reinforce health messages, would
reduce the incidence of GDM. Secondary aims included
limiting GWG to within the BMI-speciﬁc Institute of
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Medicine (IOM) recommendations [14], and reducing the
incidence of infants born LGA. Incidence of GDM was
assessed at 28 weeks’ gestation by an oral glucose tolerance
test, total GWG was calculated as the last measured weight
between 36 weeks’ gestation and delivery minus the weight
at the ﬁrst appointment, and incidence of LGA was deﬁned
as birthweight centile >90th centile using GROW centiles
[15]. Alongside three visits reinforcing messages about
healthy eating and exercise, all women in the intervention
group were provided with a smartphone app, where they
could ﬁnd recipes, exercise tips and a ‘tip of the day.’ The
control group received standard care.

Economic evaluation
The economic evaluation was conducted from the perspective of the publicly-funded health and social care system in Ireland. Analysis was performed by intention-to-treat
using all available cases. Costs were calculated from time of
ﬁrst antenatal care appointment through delivery. Unit costs
for outpatient visits associated with providing the intervention were calculated based on the amount of time visits
took, the health care provider involved, and the average
salary of that health care provider, taken from the 2017 Irish
Health Service Executive (HSE) salary scales [16]. Total
staff costs were adjusted to include social insurance, pension, and overheads, as recommended by the Guidelines for
the Economic Evaluation of Health Technologies in Ireland
(Table S1) [17]. Number of antenatal admissions and unit
costs for medical care associated with antenatal admissions
and delivery were derived from Diagnosis-Related Groups
(DRGs), recorded by the Hospital In-Patient Enquiry
(HIPE) department. After each episode, staff from the HIPE
department review patients’ charts and input all medical
interventions, medications, and visits from health care
professionals into their computer system. An algorithm
processes this information and assigns each antenatal
admission or delivery episode a DRG code, along with the
number of days spent in hospital. We obtained these data
for each patient in our sample and matched them to the
estimated cost per DRG (adjusted for length of stay) that is
provided in the HSE Ready Reckoner [18]. Costs provided
in the Ready Reckoner are calculated as national averages
adjusted to take account of hospital variation. We used these
costs to estimate the cost of care for participants in both the
intervention and control groups. All hospitals in the Irish
health system are currently transitioning to a model of
funding that allocates resources to hospitals based on
average prices for DRGs (known as “Activity-Based
Funding”) [19], and is therefore a relevant way of estimating costs in an economic evaluation. Costs of developing the mobile health application were included as in the
future the technology would need to be upgraded and re-
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designed to be context-speciﬁc; these costs included programming development on both Android and Apple platforms, as well as 30 hours of clinical nutritionist time to
develop content. No discounting was applied as the time to
follow-up was <1 year. Analyses were conducted in R
version 3.5.1 and Stata version 15.1 The code is available
upon request.

Outcomes
A core outcome set for studies on obesity in pregnant
patients does not yet exist; a protocol describing a study for
its development has recently been published [20]. The
health outcomes used in this analysis were GWG (kg),
incidence of GWG exceeding IOM guidelines, qualityadjusted life years (QALYs), and incidence of LGA. For
binary outcomes, two-sample tests of proportions were
used. For continuous outcomes and costs, two-sample t tests
were used. Previous analyses of the PEARs trial considered
a wide range of primary and secondary outcomes and
applied an adjustment for multiple hypothesis testing [13];
in this paper we use a limited set of outcomes, chosen to
facilitate comparison with other published studies, and do
not adjust for multiple outcomes. We do not explore the
cost-effectiveness of the PEARs trial for reducing the
incidence of GDM as there was no difference in incidence
between the intervention and control groups.
The PEARs trial did not measure QALYs directly. To
obtain a measure of QALYs, we converted kilograms of
GWG to the expected number of QALYs lost. We applied
an analysis from a 2009 IOM report that estimates expected
QALYs lost due to outcomes of infant mortality, postpartum weight retention and childhood obesity for each
maternal BMI category and value of GWG [21]. Using a
range of epidemiological data, the IOM analysis ﬁrst estimates the probability of each outcome by GWG, controlling
for pre-pregnancy BMI category, and the associated
expected number of QALYs lost over the lifetime of the
mother and child. The analysis then calculates the total
expected QALYs lost by GWG and BMI (Table S2 and Fig.
S1), which we merged with our data to obtain expected
QALYs lost for each participant in the study (rounded to the
nearest kg). Since the IOM report only calculates QALYs
lost for GWG between 0 and 30 kg, we set GWG to 0 kg for
women with negative GWG (n = 5) and to 30 kg for women
with GWG > 30 kg (n = 2). We interpreted the difference in
QALYs lost between intervention and control groups as the
QALYs gained as a result of the intervention.
Incremental cost-effectiveness ratios (ICERs) were calculated as cost per QALY gained, cost per kg of GWG
avoided, cost per case of excessive GWG averted and cost
per case of LGA averted. Non-parametric bootstrapping
using 5000 resamples was used to characterise uncertainty,
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which were plotted using cost-effectiveness planes and costeffectiveness acceptability curves (CEAC). Costeffectiveness planes plot the bootstrapped pairs, with the
difference in effect on the x-axis and the difference in cost
on the y-axis for the intervention compared with the control.
The CEACs represent the probability that the intervention is
cost-effective, compared with the control, across a range of
willingness-to-pay ratios up to €45,000 per QALY, which is
Ireland’s ofﬁcial threshold [22]. The National Institute for
Health and Care Excellence (NICE) consider that UK-based
interventions that cost the National Health Service less than
£20,000 per QALY gained are cost effective [23].

Sensitivity analysis
To evaluate the robustness of our ﬁndings, we conducted a
sensitivity analysis using a per-protocol analysis, in which
participants were excluded if they did not attend all three
consultation visits. We re-calculated ICERs for all outcomes
and compared with our base-case results.

Results
Sample size
Five hundred and sixty-ﬁve women were recruited into the
PEARs trial and were randomly allocated to receive either
the ‘healthy lifestyle package’ or standard care. Nineteen
women had no information on delivery costs (ten in control,
nine in the intervention group): two had congenital or foetal
anomalies, four had miscarriages, eight did not return to the
hospital for delivery, and ﬁve had missing cost data most
likely due to error in assignment of hospital ID numbers.
Two hundred and six women (99 in the control and 107 in
the intervention groups) were missing gestational weight
gain data as a result of not appearing at the antenatal
appointment when it was measured. Twenty-four women
were missing infant size data (13 in the control and 11 in the
intervention). Our analyses included all available cases.
There were no signiﬁcant differences between the intervention group (n = 278) and the control group (n = 287) in
demographic characteristics at baseline (Table 1). There
were also no differences in baseline characteristics between
women with recorded gestational weight gain compared to
the full sample (Table 1).

PEARs effectiveness
The proportion of women who developed GDM did not
differ between the two groups [13]. Women in the intervention group gained signiﬁcantly less weight compared
with women in the control group (11.3 kg vs 12.6 kg, P =
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Table 1 Baseline characteristics
of the PEARs cohort.

Full sample
Characteristic

Intervention
(n = 278)

Control
(n = 287)

All (n = 565)

Participants with GWG data
available
n = 359

Age—years

32.8 ± 4.6

32.2 ± 4.2

32.5 ± 4.4

32.4 ± 4.4

Primiparous—no. (%)
138 (49.6)
Body mass index category—no. (%)

153 (53.3)

291 (51.5)

181 (50.4)

Overweight, 25–29.9 kg/m2
Obese class I, 30–34.9 kg/m2

184 (66.2)
71 (25.5)

195 (67.9)
73 (25.4)

379 (67.1)
144 (25.5)

243 (67.7)
90 (25.1)

Obese class II, ≥35 kg/m2
Educational attainment—no. (%)

23 (8.3)

19 (6.6)

42 (7.4)

26 (7.2)

7 (2.7)

6.0 (2.2)

Some 2nd-level
Completed 2nd-level
Some 3rd-level
Completed 3rd-level
Ethnicity is white—no. (%)

13 (2.4)

9 (2.6)

35 (13.4)
67 (25.6)

35 (12.6)
46 (16.6)

70 (13.0)
113 (21.0)

47 (13.6)
72 (20.9)

153 (58.4)
257 (94.8)

190 (68.6)
255 (91.1)

343 (63.6)
512 (92.3)

217 (62.9)
324 (92.1)

Age missing for four control and seven intervention participants. Education missing for 10 control and 16
intervention participants. Ethnicity missing or unspeciﬁed for seven control and seven intervention
participants.
Plus–minus values are means ± standard deviation, GWG gestational weight gain.

0.03). Women in the intervention group were also less
likely to exceed IOM GWG guidelines (50.9% vs 63.8%,
P = 0.01). When we converted absolute GWG to QALYs
lost, women in the intervention group lost fewer QALYs,
though the difference was not statistically signiﬁcant (2.75
vs 2.85, P = 0.38). Finally, infants of mothers in the intervention group were signiﬁcantly less likely to be born LGA
than infants born to mothers in the control group (4.1% vs
8.7%, P = 0.03).

Costs
The cost associated with providing the mobile health
intervention was €152 per person (Table 2). There were no
signiﬁcant differences across intervention and control
groups in mean cost of antenatal admissions (P = 0.42),
delivery costs (P = 0.63) or total health care utilisation
(P = 0.43). Total cost of the intervention including health
care utilisation was slightly higher in the intervention group,
though this difference was not statistically signiﬁcant
(P = 0.08).

GWG and LGA were €2117 and €5911 per case averted,
respectively (Table 3). 95% or more of bootstrap pairs were
located in the NE quadrant for these three outcomes. The
CEAC for kg of GWG avoided reached a conﬁdence level
of 95% at €905, indicating that if one is willing to pay a
maximum of an additional €905 per kg of GWG avoided,
there is a 95% probability that the intervention is costeffective (Fig. 2). The CEAC for case of LGA averted
reached a conﬁdence level of 95% at €25,737 (Fig. 3). The
CEAC for case of excessive GWG averted reached a conﬁdence level of 95% at €7090.

Sensitivity analysis
Seventy-two participants were excluded in the per-protocol
analysis (32 in the control group, 40 in the intervention
group). Results of average costs of health care utilisation in
the per-protocol analysis were similar to the base-case
analysis (Table S3). Cost of antenatal care and delivery was
similar in the intervention and control groups (Table S3).
Results on cost-effectiveness were very similar to the basecase analysis, albeit with slightly lower ICERs (Table 3).

Cost-effectiveness
The ICER for QALYs was €2914 per QALY gained
(Table 3). More than 77% of bootstrap pairs were located in
the northeast (NE) quadrant, indicating that the PEARs
intervention is likely to be more expensive and more
effective with regards to QALYs than usual care. At a
threshold of €20,000 per QALY, the probability that PEARs
is cost-effective is 77% (Fig. 1), while at €45,000 per
QALY, the probability is 79%. The ICER for GWG was
€209 per kg of weight avoided and the ICERs for excessive

Discussion
Main ﬁndings
This study contributes to our understanding of the costs and
consequences of a lifestyle intervention for prevention of
GDM; in particular, we are the ﬁrst study to examine
whether using a mobile phone-based programme can be a
cost-effective way of improving maternal and infant
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Table 2 Cost of the PEARs
intervention and health care
utilisation per person (all costs
in 2017 euro, €).

Intervention

1003
Difference (SE) P value

Control

Mean (SD)

n

71.94

278 –

–

–

N/A

Consultation visit 1

60.28

278 –

–

–

N/A

Consultation visit 2b

7.54

278 –

–

–

N/A

Consultation visit 3b

9.74

278 –

–

–

N/A

Consultation emailsc

1.84

278 –

–

–

N/A

0.48

278 –

–

–

N/A

269 374 (706)

276 56 (69)

0.42

Cost item

Mean (SD)

n

Intervention costs
Mobile health applicationa
b

Text reminders for visits

c

Total intervention cost per person

151.82

Health care utilisation costs
Average antenatal admissions costs

430 (913)

Delivery costs
Caesarean + CSCC

7198 (3950) 17

6879 (2593) 14

319 (1230)

0.80

Caesarean -CSCC

4782 (91)

56

4765 (0)

60

17 (12)

0.14

Vaginal + OR PR + CSCC

4029 (0)

2

4029 (0)

2

0

1

Vaginal + OR PR -CSCC

3036 (0)

4

3036 (0)

3

0

1

Vaginal

2320 (50)

190 2316 (0)

Average delivery costs

3164 (1739) 269 3097 (1446) 276 73 (137)

0.63

Total health care utilisation cost
per person

3593 (1986) 269 3471 (1648) 276 122 (154)

0.43

Total cost per person, intervention +
health care utilisation

3745 (1986)

0.08

3471 (1648)

198 4 (4)

274 (154)

0.31

CSCC Catastrophic or Severe Complication or Comorbidity, OR PR Operating Room or Procedure.
The total cost of the mobile health application was €20,000, which included both application and content
development. We divided total cost by the number of intervention participants.
a

b
The ﬁrst consultation was with a nutritionist (hourly cost €30.14) and took ~2 h. The second consultation
was also with a nutritionist and took ~15 min. The third consultation was with an obstetrician (hourly cost
€38.94) and took ~15 min. Costs associated with these consultations were calculated based on the HSE
salary scales for these healthcare professionals, including social insurance, pension, and overheads. Details
are in the Table S3.
c

A nutritionist was tasked with sending pre-prepared emails to intervention participants every two weeks
(17 h total) and with tracking the participants to remind them to attend their research-related visits (4.42 h
total). The cost per participant for these activities was estimated by dividing the total time by the number of
intervention participants.

outcomes among pregnant women with an elevated BMI.
Our results indicate that the cost of inpatient and outpatient
maternal care and delivery did not signiﬁcantly differ
between the treatment and control groups at a threshold of
P < 0.05, even when the cost of the intervention was
included. This is important given the clinical beneﬁts
observed in terms of reducing GWG and a reduced risk of
LGA. Assuming a ceiling ratio of €45,000, the probability
that the intervention was cost‐effective was 79% based on
QALYs, indicating that the intervention may be costeffective. The cost per LGA case averted was €5911, while
the cost of avoiding an additional kilogram of GWG was
€209 and the cost per case of excess GWG averted was
€2117. As of yet, no detailed analysis of the health effects
or costs saved from reduction in risk of LGA or macrosomia
exist, which would provide guidance as to a reasonable
willingness-to-pay threshold for this outcome.

The 13% point reduction in risk of excessive GWG
observed in this study is clinically relevant as women who
gain weight in excess of the IOM recommendations are at
increased risk of negative health outcomes, as are their
children [21]. Reducing GWG is an important public health
goal as, in Ireland, over half of women with an elevated
BMI gain excessive weight during pregnancy [2, 24].
Reducing GWG could provide substantial savings to the
health care system by reducing a woman’s risk of future
weight retention [25, 26] and lifetime risk of obesity and
type 2 diabetes [6, 27]. In addition, infants born LGA, for
which excessive GWG is a risk factor independent of
maternal BMI [28], are more likely to be obese themselves
throughout the life course [4, 5, 29], and are more likely to
develop both type 1 and type 2 diabetes [30, 31], which
increases their lifetime medical costs [32, 33]. Thus, the
PEARs intervention has the potential to result in long-term
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Table 3 Cost-effectiveness estimates of PEARs (all costs in euro, €).
Sample size

ICER analysis

Intervention

Control

Incremental cost

QALYs gained

171

188

274

GWG (kg reduced)

171

188

274

Distribution on costeffectiveness plane (%)
Incremental effect

ICER

NE

SE

SW

NW

Main analysis
0.09 (−0.12 to 0.31) 2914
1.3 (0.15–2.49)

209

77.1

3.1

0.7

19.1

95.0

3.8

0.0

1.1

Excessive GWG (risk reduced)

171

188

274

0.13 (0.03–0.23)

2117

95.7

3.8

0.0

0.5

LGA (risk reduced)

267

274

274

0.046 (0.01–0.09)

5911

94.9

3.8

0.1

1.3

154

172

210

0.12 (−0.10 to 0.34) 1723

77.0

9.2

1.3

12.5

Per protocol analysis
QALYs gained
GWG (kg reduced)

154

172

210

1.4 (0.18–2.6)

154

88.5

10.4

0.1

1.0

Excessive GWG (risk reduced)

154

172

210

0.15 (0.04–0.25)

1440

89.0

10.5

0.0

0.5

LGA (risk reduced)

233

248

210

0.046 (0.002–0.09)

4592

87.6

10.2

0.3

1.9

GWG gestational weight gain, LGA large-for-gestational-age, QALY Quality adjusted life year, ICER incremental cost-effectiveness ratio, NE
northeast, SE southeast, SW southwest, NW northwest.

savings. However, our analysis is limited to the time period
from ﬁrst antenatal care appointment to delivery and we are
not able to measure the reduction in health care costs in the
long-term for either mother or infant via reduced GWG. We
are therefore not able to determine whether the health care
service would see long-term savings as a result of this
intervention.
An important consideration of our analysis is the choice
of the health care system perspective, rather than a societal
perspective. A societal perspective would also take into
account participant costs, including travel costs, diet and
exercise costs, and opportunity costs. We chose the health
care system perspective for several reasons. First, it is
speciﬁed as the reference case perspective in both the
guidelines of the Health Information and Quality Authority
in Ireland and the NICE in the UK. This perspective
therefore facilitates comparison of cost-effectiveness across
economic evaluations of health interventions with different
health outcomes. Second, the long-run aim of this study
would be to integrate PEARs into routine maternity services. In this case, participants would conduct their PEARs
visits during the course of their normal antenatal care, and
therefore would not incur extra travel costs or opportunity
costs for their time on these visits. The phone application
itself is able to be used at any time that is convenient for
participants, and therefore minimises opportunity costs for
women compared to other lifestyle interventions. It is possible, however, that participants would incur higher diet and
exercise costs. While the PEARs study was not designed to
measure these costs in detail, we do have some evidence
that these costs were not substantially increased for participants. In their exit interview, participants were asked
whether they felt that their weekly grocery bill increased as
a result of the intervention, with responses on a 5-point

Likert scale from strongly agree to strongly disagree. Most
participants responded that their costs did not increase: 77%
of participants agreed or strongly agreed that their diet costs
did not increase as a result of the intervention, 11% did not
agree or disagree with the statement, and 11% believed that
their costs did increase. However, it is important to
acknowledge this limitation in that patient costs were not
considered in this analysis.
While there are many randomised trials evaluating the
effectiveness of lifestyle interventions for prevention of
GDM, few examine cost-effectiveness [10, 11, 34]. We
identiﬁed three trials with associated economic evaluations.
Similar to our results, none of the trials identiﬁed reported
signiﬁcant effects on QALYs. The results reported in this
study on cost-effectiveness with respect to infant outcomes
were consistent with those observed in the NELLI trial in
Finland [35] and the LIMIT study in Australia [36]; both
trials focused on dietary and physical activity counselling.
However, FitFor2, a trial conducted in the Netherlands [37]
that focused solely on physical activity was both costlier
and less effective than other trials, suggesting that dietary
counselling in lifestyle interventions is an important aspect
of cost-effectiveness. Although the PEARs trial involved a
similar number of total contacts with the health care system
as the NELLI and LIMIT trials, PEARs participants had
access to a mobile phone application that allowed them to
access information on diet and exercise at any time. This
additional intervention component did not result in an
intervention that was costlier than others described in the
literature, but did result in a larger effect on GWG. Participants in the PEARs trial used the app often: the median
(IQR) of total instances of use was 24 (8–72) and the
median (IQR) for instances of use per week was 1.75
(0.71–3.49). Consistent access to information, in
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Fig. 1 Cost-effectiveness plane
(top) and acceptability curve
(bottom) for quality-adjusted
life years (QALYs). The top
ﬁgure shows the difference in
QALYs gained on the x-axis and
the difference in cost on the yaxis for the intervention
compared with the control. The
bottom ﬁgure represents the
probability that the intervention
is cost-effective, compared with
the control, for a given
willingness-to-pay ratio.
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conjunction with regular meetings with health care staff,
may have improved GWG outcomes at a low cost to the
health care system. A randomised trial of a text messaging

intervention for pregnant women in Australia also found
signiﬁcant reductions in GWG [38]. Lastly, a large proportion of the intervention’s cost per participant was for
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Fig. 2 Cost-effectiveness plane
(top) and acceptability curve
(bottom) for gestational weight
gain (GWG). The top ﬁgure
shows the difference in kg in
weight gain on the x-axis and the
difference in cost on the y-axis
for the intervention compared
with the control. The bottom
ﬁgure represents the probability
that the intervention is costeffective, compared with the
control, for a given willingnessto-pay ratio.
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development of the mobile application; the intervention
may be more cost-effective when considering scaling up its
use to a larger population.

It is possible that it is more effective in terms of health
outcomes to conduct an intervention pre-pregnancy with the
aim of increasing the proportion of women beginning
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Fig. 3 Cost-effectiveness plane
(top) and acceptability curve
(bottom) for case of large-forgestational age (LGA). The top
ﬁgure shows the difference in
risk of LGA on the x-axis and
the difference in cost on the yaxis for the intervention
compared with the control. The
bottom ﬁgure represents the
probability that the intervention
is cost-effective, compared with
the control, for a given
willingness-to-pay ratio.

1007

0



−500

−1000
−0.2

−0.1

0.0

0.1

0.2

Incremental effect

1.0

0.9

Probability of cost−effectiveness

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

0.0
0

5000

10000

15000

20000

25000

30000

35000

40000

45000

Willingness to pay per LGA averted (€)

pregnancy with a BMI within the normal range. This is
likely to be most beneﬁcial in terms of QALYs; previous
research suggests that among women with a normal BMI,

increasing GWG does not lead to an increase in QALYs lost
to the same extent it does among women with an elevated
BMI [21]. However, identifying women planning a
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pregnancy and following them up over time would require
considerable time and such an intervention would likely be
very costly. Women typically do not access preconception
health services [39]; as such, a sustained period of increased
contact points with health care professionals—i.e. during
pregnancy—is still likely to be the most effective time to
intervene. An alternative to conducting an intervention prepregnancy would be to conduct an intervention among
women with a BMI within the normal range with an aim of
limiting their GWG, which would reduce their risk of
beginning future pregnancies at an elevated BMI. A protocol for such a trial has been published [40].

Strengths and limitations
This analysis makes an important contribution to the literature as there is currently a dearth of cost-effectiveness
information available for lifestyle interventions to reduce
risk of GDM. If interventions are to be scaled-up and
implemented within health care systems, an understanding
of the costs and beneﬁts is essential.
This study has limitations. First, costs were calculated
only from pregnancy to delivery; downstream medical costs
could substantially impact cost-effectiveness estimates. A
seven-year follow up of the NELLI trial found that the mean
cumulative cost of the intervention group was 30.6% lower
than in the usual care group; however, this difference was
not statistically signiﬁcant [41]. Second, we considered the
health care system perspective in our evaluation to provide a
policy-relevant analysis. A societal perspective that includes
patient costs may impact on the cost-effectiveness results.
Third, we do not measure QALYs directly, but estimate
QALYs from secondary data. Modelling QALYs lost using
secondary data has several limitations. First, it introduces
uncertainty into our analysis because the link between GWG
and QALYs was estimated with available IOM data, the data
in that analysis were gathered from a variety of sources with
varying sample size, and the respondents in the IOM data
may not be representative of the participants in PEARs.
Second, the IOM analysis focused on several key endpoints
(infant mortality, postpartum weight retention, and childhood obesity) because these were deemed to be quantitatively important and reasonably estimated [21]. However,
other aspects of quality of life such as mental health, social
functioning, and pain would not be included in this analysis.
While measuring QALYs directly would be preferable, our
results are similar to those of three other lifestyle intervention trials that used three different methods for measuring
QALYS —via the health-related quality of life (HRQoL)
15D questionnaire [35], via the SF36 health survey [36], and
via the EuroQol-5D questionnaire [37]. None found a signiﬁcant impact on QALYs and our point estimate lies in
between the estimates calculated in these studies.

E. J. O’Sullivan et al.

Finally, the results of this study may not be generalisable
to other populations, where health care costs and phone
ownership usage may be different.

Conclusion
Providing a mobile health-supported lifestyle intervention to
pregnant women with an elevated BMI may be a costeffective way of improving maternal and infant health. Formative qualitative research exploring the factors inﬂuencing
dietary choices among pregnant women with an elevated BMI
will help inform future intervention development [42].
Additional research on the cost-effectiveness of lifestyle
interventions is needed to understand the mechanisms of costeffective interventions and the long-term costs and consequences for both mother and child. It may be prudent to
conduct interventions aiming to increase the proportion of
women beginning pregnancy with a BMI within the normal
range. Such interventions may be more beneﬁcial for both
maternal and infant health and more cost-effective.
Funding The PEARs trial received funding from The National
Maternity Hospital Medical Fund (Dublin, Ireland) and University
College Dublin (Ireland), the authors received no additional funding to
conduct the present analysis.
Author contributions EJOS and SR were involved in the conception,
planning, carrying out, interpreting and writing up of the work. SR
conducted cost-effectiveness analyses. MK and KA were involved in
the conception and writing up of the work. FMcA oversaw all aspects
of the work and is responsible for the ﬁnal content.

Compliance with ethical standards
Conﬂict of interest The authors declare that they have no conﬂict of
interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional afﬁliations.

References
1. Motee A, Jeewon R. Importance of exclusive breastfeeding and
complementary feeding among infants. Curr Res Nutr Food Sci.
2014;2:17.
2. Walsh JM, McGowan CA, Mahony RM, Foley ME, McAuliffe
FM. Obstetric and metabolic implications of excessive gestational
weight gain in pregnancy. Obesity. 2014;22:1594–1600.
3. Chu SY, Callaghan WM, Bish CL, D’Angelo D. Gestational
weight gain by body mass index among US women delivering live
births, 2004-2005: fueling future obesity. Am J Obstet Gynecol.
2009;200:271.e271–271.e277.
4. Mamun A, Mannan M. Gestational weight gain in relation to
offspring obesity over the life course: a systematic review and
bias‐adjusted meta‐analysis. Obes Rev. 2014;15:338–47.
5. Schack-Nielsen L, Michaelsen KF, Gamborg M, Mortensen EL,
Sørensen TI. Gestational weight gain in relation to offspring body

Cost-effectiveness of a mobile health-supported lifestyle intervention for pregnant women with an. . .

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.
17.

18.

19.

20.

21.

22.

23.

mass index and obesity from infancy through adulthood. Int J
Obes. 2010;34:67.
Amorim AR, Rössner S, Neovius M, Lourenço PM, Linné Y.
Does excess pregnancy weight gain constitute a major risk for
increasing long‐term BMI? Obesity. 2007;15:1278–86.
Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev.
2011;12:131–41.
Morgan KL, Rahman MA, Hill RA, Khanom A, Lyons RA,
Brophy ST. Obesity in pregnancy: infant health service utilisation
and costs on the NHS. BMJ Open. 2015;5:1.
Kuhle S, Muir A, Woolcott CG, Brown MM, McDonald SD,
Abdolell M, et al. Maternal pre-pregnancy obesity and health care
utilization and costs in the offspring. Int J Obes. 2019;43:735–43.
Bain E, Crane M, Tieu J, Han S, Crowther CA, Middleton P. Diet
and exercise interventions for preventing gestational diabetes
mellitus. Cochrane Database Syst Rev. 2015;1:CD010443. https://
doi.org/10.1002/14651858.CD010443.pub2.
Tieu J, Shepherd E, Middleton P, Crowther CA. Dietary advice
interventions in pregnancy for preventing gestational diabetes
mellitus. Cochrane Database Syst Rev. 2017;1:1.
Kennelly MA, Ainscough K, Lindsay K, Gibney E, Mc Carthy M,
McAuliffe FM. Pregnancy, exercise and nutrition research study
with smart phone app support (Pears): study protocol of a randomized controlled trial. Contemp Clin Trials. 2016;46:92–9.
Kennelly MA, Ainscough K, Lindsay KL, O’Sullivan E, Gibney
ER, McCarthy M, et al. Pregnancy exercise and nutrition with
smartphone application support: a randomized controlled trial.
Obstet Gynecol. 2018;131:818–26.
National Research Council. Weight gain during pregnancy:
reexamining the guidelines. National Academies Press, Birmingham, UK, 2010.
Gardosi J, Francis A. Customised weight centile calculator.
GROW version 6.7.8.5(IE). Gestation Network, Birmingham,
UK, 2016.
Health Service Executive. April 2017 revised consolidated payscales. In Edited by Health Service Executive; 2017.
Health Information and Quality Authority. Guidelines for the
economic evaluation of health technologies in Ireland. Dublin:
HIQA; 2014.
National Casemix Pogramme of the Health Services Executive.
Ready reckoner of acute hospital inpatient and daycase activity &
costs (summarised by DRG) relating to 2011 costs and activity. In.
Edited by Programme NC; 2013.
Health Service Executive. Activity-based funding programme:
Implementation Plan 2015–2017. Ireland, Health Service Executive, 2015. https://assets.gov.ie/40185/74ffe4e1dc104cd6856b5a
32375d8d5f.pdf. Accessed 15 Jan 2020.
Dadouch R, Faheim M, Juando-Prats C, Parsons J, D’Souza R.
COSSOPP Investigators Development of a Core Outcome Set for
Studies on Obesity in Pregnant Patients (COSSOPP): a study
protocol. Trials. 2018;19:655
Hammitt JK. Optimal gestational weight gain: risk tradeoff calculations. Appendix G, Part IV, 674-683 in Institute of Medicine
Committee on Reexamination of Pregnancy Weight Guidelines,
Weight gain during pregnancy: reexamining the guidelines.
Washington, D.C.: National Academies Press; 2009.
O’Mahony JF, Coughlan D. The Irish cost-effectiveness threshold: does it support rational rationing or might it lead to unintended harm to Ireland’s health system? PharmacoEconomics.
2016;34:5–11.
National Institute for Health and Care Excellence. Developing
NICE guidelines: the manual. London, UK: National Institute for
Health and Care Excellence; 2018.

1009

24. Heery E, Kelleher CC, Wall PG, McAuliffe FM. Prediction of
gestational weight gain—a biopsychosocial model. Public Health
Nutr. 2015;18:1488–98.
25. Haugen M, Brantsæter AL, Winkvist A, Lissner L, Alexander J,
Oftedal B, et al. Associations of pre-pregnancy body mass index
and gestational weight gain with pregnancy outcome and postpartum weight retention: a prospective observational cohort study.
BMC Pregnancy Childbirth. 2014;14:201.
26. Nehring I, Schmoll S, Beyerlein A, Hauner H, von Kries R.
Gestational weight gain and long-term postpartum weight retention: a meta-analysis. Am J Clin Nutr. 2011;94:1225–31.
27. Rooney BL, Schauberger CW, Mathiason MA. Impact of perinatal
weight change on long-term obesity and obesity-related illnesses.
Obstet Gynecol. 2005;106:1349–56.
28. Ferraro Z, Barrowman N, Prud’Homme D, Walker M, Wen S,
Rodger M, et al. Excessive gestational weight gain predicts large
for gestational age neonates independent of maternal body mass
index. J Matern-Fetal Neonatal Med. 2012;25:538–42.
29. Yu Z, Han S, Zhu G, Zhu C, Wang X, Cao X, et al. Birth weight
and subsequent risk of obesity: a systematic review and meta‐
analysis. Obes Rev. 2011;12:525–42.
30. Harder T, Roepke K, Diller N, Stechling Y, Dudenhausen JW,
Plagemann A. Birth weight, early weight gain, and subsequent
risk of type 1 diabetes: systematic review and meta-analysis. Am J
Epidemiol. 2009;169:1428–36.
31. Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A. Birth weight and subsequent risk of type 2 diabetes: a
meta-analysis. Am J Epidemiol. 2007;165:849–57.
32. Dee A, Kearns K, O’Neill C, Sharp L, Staines A, O’Dwyer V,
et al. The direct and indirect costs of both overweight and obesity:
a systematic review. BMC Res Notes. 2014;7:242.
33. Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of
treating type 2 diabetes and diabetic complications. Am J Prev
Med. 2013;45:253–61.
34. Han S, Middleton P, Crowther CA. Exercise for pregnant women for
preventing gestational diabetes mellitus. Cochrane Database Syst Rev.
2012;1:CD009021. https://doi.org/10.1002/14651858.CD009021.pub2.
35. Kolu P, Raitanen J, Rissanen P, Luoto R. Cost-effectiveness of
lifestyle counselling as primary prevention of gestational diabetes
mellitus: ﬁndings from a cluster-randomised trial. PLoS ONE.
2013;8:1–12.
36. Dodd JM, Ahmed S, Karnon J, Umberger W, Deussen AR, Tran
T, et al. The cost-effectiveness of providing antenatal lifestyle
advice for women who are overweight or obese: the LIMIT randomised trial. BMC Obes. 2015;2:14.
37. Oostdam N, Bosmans J, Wouters MG, Eekhoff EM, van
Mechelen W, van Poppel MN. Cost-effectiveness of an exercise
program during pregnancy to prevent gestational diabetes: results
of an economic evaluation alongside a randomised controlled trial.
BMC Pregnancy Childbirth. 2012;12:64.
38. Willcox J, Wilkinson S, Lappas M, Ball K, Crawford D,
McCarthy E, et al. A mobile health intervention promoting healthy
gestational weight gain for women entering pregnancy at a high
body mass index: the txt4 two pilot randomised controlled trial.
BJOG: Int J Obstet Gynaecol. 2017;124:1718–28.
39. Stephenson J, Patel D, Barrett G, Howden B, Copas A, Ojukwu O,
et al. How do women prepare for pregnancy? Preconception
experiences of women attending antenatal services and views of
health professionals. PLoS ONE. 2014;9:e103085.
40. Dodd JM, Deussen AR, Louise J. Optimising gestational weight
gain and improving maternal and infant health outcomes through
antenatal dietary, lifestyle and physical activity advice: the
OPTIMISE randomised controlled trial protocol. BMJ Open.
2018;8:e019583.

1010
41. Kolu P, Raitanen J, Puhkala J, Tuominen P, Husu P, Luoto R.
Effectiveness and cost-effectiveness of a cluster-randomized prenatal lifestyle counseling trial: a seven-year follow-up. PloS ONE.
2016;11:e0167759.

E. J. O’Sullivan et al.
42. O’Brien OA, Lindsay KL, McCarthy M, McGloin AF, Kennelly
M, Scully HA, et al. Inﬂuences on the food choices and physical
activity behaviours of overweight and obese pregnant women: a
qualitative study. Midwifery. 2017;47:28–35.

